We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BrightSpring's Care Ratings Climb: Is Its Lead Sustainable?
Read MoreHide Full Article
Key Takeaways
BrightSpring saw 80% of Home Health branches rated 4 stars or better, with declining hospitalization rates.
BTSG's Hospice operations outperformed, with visit time 50% above average and record-high quality scores.
BTSG's Infusion segment posted a 96% therapy completion rate and 95% patient satisfaction score.
BrightSpring Health Services, Inc.’s (BTSG - Free Report) investments in process improvements, including new and enhanced technologies, play a strategically vital role in helping improve the efficiency of care delivery and outcomes for the patients. In line with this, within the Home Health segment, over 80% of branches achieved a 4-star or better rating, with 60-day hospitalization rates continuing to decline and patient satisfaction nearing 90% — all reflecting improved process execution and technological enhancements.
The company’s Hospice operations remain a standout, with visit frequency and time spent with patients exceeding the national average by 50%, and quality index scores reaching record highs. In the Rehab segment, patient satisfaction remained strong at 98%, while the Personal Care segment achieved its highest-ever rating with a 4.6 out of 5 satisfaction score. Community Living also delivered superior performance, recording its lowest number of audit findings to date — 40% better than the industry average.
BrightSpring’s Infusion segment reported a 96% therapy completion discharge rate and a 95% patient satisfaction score, while its Home and Community Pharmacy Services achieved near-perfect operational metrics, including 99.999% dispense accuracy and 99% order completeness.
Together, these results underscore the company’s ability to meet the evolving needs of a diverse patient base. The company’s ability to ensure high-quality outcomes across complementary services reinforces its pivotal role in shaping the future of home and community health care.
Key Competitors Challenging BTSG
Amedisys (AMED - Free Report) , a key competitor of BrightSpring, focuses on clinical distinction through its Quality of Patient Care and Patient Satisfaction star ratings. The company strives for a 4.0 Quality of Patient Care star rating across all its care centers and has implemented targeted action plans to enhance patient care and foster a culture of quality. In the Centers for Medicare and Medicaid Services’ January 2025 Final release, Amedisys successfully maintained this goal, achieving an average Quality of Patient Care star rating of 4.18 across all providers. 88% of its care centers received a rating of 4 stars or higher, with 11 centers earning a perfect 5-star rating. Additionally, Amedisys' Patient Satisfaction star average was 4.02, surpassing the industry average.
Addus HomeCare Corporation (ADUS - Free Report) has launched the Care Advantage Program to close gaps in preventive care by partnering with insurers to offer services like wellness visits and lab tests. It uses data-driven tools to monitor patient health and guide timely care transitions across services. By focusing on chronic condition management, personalized care plans, and regular follow-ups, Addus aims to boost outcomes, reduce hospitalizations, and enhance patient satisfaction through a tech-enabled, patient-centered approach.
BTSG’s Price Performance, Valuation and Estimates
Shares of BrightSpring have gained 104.1% in the past year against the industry’s 21.7% decline. The S&P 500 composite grew 11.3% in the same period.
Image Source: Zacks Investment Research
From a valuation standpoint, BTSG trades at a forward price-to-earnings ratio of 21.59, above the industry’s 14.25.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for BTSG’s earnings has been on the rise over the past 30 days.
Image: Bigstock
BrightSpring's Care Ratings Climb: Is Its Lead Sustainable?
Key Takeaways
BrightSpring Health Services, Inc.’s (BTSG - Free Report) investments in process improvements, including new and enhanced technologies, play a strategically vital role in helping improve the efficiency of care delivery and outcomes for the patients. In line with this, within the Home Health segment, over 80% of branches achieved a 4-star or better rating, with 60-day hospitalization rates continuing to decline and patient satisfaction nearing 90% — all reflecting improved process execution and technological enhancements.
The company’s Hospice operations remain a standout, with visit frequency and time spent with patients exceeding the national average by 50%, and quality index scores reaching record highs. In the Rehab segment, patient satisfaction remained strong at 98%, while the Personal Care segment achieved its highest-ever rating with a 4.6 out of 5 satisfaction score. Community Living also delivered superior performance, recording its lowest number of audit findings to date — 40% better than the industry average.
BrightSpring’s Infusion segment reported a 96% therapy completion discharge rate and a 95% patient satisfaction score, while its Home and Community Pharmacy Services achieved near-perfect operational metrics, including 99.999% dispense accuracy and 99% order completeness.
Together, these results underscore the company’s ability to meet the evolving needs of a diverse patient base. The company’s ability to ensure high-quality outcomes across complementary services reinforces its pivotal role in shaping the future of home and community health care.
Key Competitors Challenging BTSG
Amedisys (AMED - Free Report) , a key competitor of BrightSpring, focuses on clinical distinction through its Quality of Patient Care and Patient Satisfaction star ratings. The company strives for a 4.0 Quality of Patient Care star rating across all its care centers and has implemented targeted action plans to enhance patient care and foster a culture of quality. In the Centers for Medicare and Medicaid Services’ January 2025 Final release, Amedisys successfully maintained this goal, achieving an average Quality of Patient Care star rating of 4.18 across all providers. 88% of its care centers received a rating of 4 stars or higher, with 11 centers earning a perfect 5-star rating. Additionally, Amedisys' Patient Satisfaction star average was 4.02, surpassing the industry average.
Addus HomeCare Corporation (ADUS - Free Report) has launched the Care Advantage Program to close gaps in preventive care by partnering with insurers to offer services like wellness visits and lab tests. It uses data-driven tools to monitor patient health and guide timely care transitions across services. By focusing on chronic condition management, personalized care plans, and regular follow-ups, Addus aims to boost outcomes, reduce hospitalizations, and enhance patient satisfaction through a tech-enabled, patient-centered approach.
BTSG’s Price Performance, Valuation and Estimates
Shares of BrightSpring have gained 104.1% in the past year against the industry’s 21.7% decline. The S&P 500 composite grew 11.3% in the same period.
Image Source: Zacks Investment Research
From a valuation standpoint, BTSG trades at a forward price-to-earnings ratio of 21.59, above the industry’s 14.25.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for BTSG’s earnings has been on the rise over the past 30 days.
Image Source: Zacks Investment Research
BTSG stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.